Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Dermatology Department, China-Japan Friendship Hospital, Beijing, China.
Front Immunol. 2024 Jun 6;15:1395288. doi: 10.3389/fimmu.2024.1395288. eCollection 2024.
An 8-year-old female child presented with patchy hair loss for 1 year, accompanied by eyebrow loss for 6 months. Microscopic examination of the hair confirmed the features of active stage alopecia areata, with a Severity of Alopecia Tool (SALT) score of 70%. The diagnosis was severe alopecia areata. The patient had a history of atopic dermatitis since infancy, with recurrent episodes of scattered papules and pruritus for 8 years. Initial treatment involved subcutaneous injections of dupilumab 300mg every 2 weeks for 6 months, resulting in a reduction of SALT score to 20% and improvement of atopic dermatitis symptoms. Discontinuation of Dupilumab and initiation of daily oral Baricitinib at a dose of 2mg for a duration of 5 months. According to the SALT score evaluation, the severity of hair loss was less than 10% and there was significant regrowth of hair. No significant adverse reactions were observed during the treatment period.
一位 8 岁女性患儿,1 年前出现斑片状脱发,6 个月前出现眉毛脱落。头发镜检证实为活动期斑秃,脱发严重程度工具(SALT)评分为 70%。诊断为严重斑秃。患儿自婴儿期起即有特应性皮炎病史,8 年来反复发作散在丘疹和瘙痒。初始治疗包括皮下注射度普利尤单抗 300mg,每 2 周 1 次,共 6 个月,SALT 评分降至 20%,特应性皮炎症状改善。停用度普利尤单抗,改为每日口服巴瑞替尼 2mg,治疗 5 个月。根据 SALT 评分评估,脱发严重程度小于 10%,头发明显再生。治疗期间未观察到明显不良反应。